The FDA has approved Pfizer’s #TUKYSA (#tucatinib) + #trastuzumab + #pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
🧪Tucatinib for research use from MedChemExpress: https://www.medchemexpress.com/Irbinitinib.html

Biocon's Pertuzumab: A Milestone Biosimilar Approved for HER2-Positive Breast Cancer #India #Bengaluru #Biocon #HER2-positive #Pertuzumab

Biocon Achieves Positive CHMP Opinion for Pertuzumab Biosimilar, A First Under EMA’s New Clinical Approach #India #Bengaluru #Biocon #Biosimilar #Pertuzumab

Biocon's Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA's New Development Approach #India #Bengaluru #Biocon #Biosimilar #Pertuzumab

Biocon's Pertuzumab Biosimilar Receives Positive CHMP Opinion: A Major Milestone in Cancer Treatment #India #Bengaluru #Biocon #Pertuzumab #Pebrilzo